COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Aldesleukin (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms COMBAT-1
- 18 Jan 2017 Time frame of primary end point has been changed fro 2 years to 3 years.
- 18 Jan 2017 Status changed from active, no longer recruiting to discontinued.
- 02 Jun 2015 Interim results (n=6) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.